GlassScriptPhysician profile
Fady Marmoush
NPI 1508207689
$10,099.47
in general payments reported to CMS, 2019-2025
38 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,932 · 2020: $2,690 · 2021: $376 · 2022: $393 · 2023: $2,031 · 2024: $1,201 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,018 · Food and Beverage: $1,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,017.71 |
| Food and Beverage | $1,690.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,479.85 | 2019-2020 | |
| Medtronic, INC. | $1,242.38 | 2021-2024 | Micra, Resolute Onyx, Venaseal |
| Edwards Lifesciences Corporation | $1,238.24 | 2020-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| W. L. Gore & Associates, INC. | $745.20 | 2024 | Gore Cardioform Septal Occluder |
| Penumbra, INC. | $681.50 | 2023 | Indigo System |
| Abiomed | $565.75 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $477.55 | 2019-2025 | |
| Abbott Laboratories | $361.34 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $305.42 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $298.49 | 2019-2024 | Farxiga |
| Boston Scientific Corporation | $276.29 | 2019-2024 | Varithena Administration Pack |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $250.45 | 2019-2025 | Lifevest |
| Heartflow, INC. | $130.12 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $118.32 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $106.82 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fady Marmoush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.